-
ASCO International Perspective | Professor Jill Hamilton Reeves: Can Enhanced Immunonutrition Improve Outcomes for Radical Cystectomy Patients?
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was held from May 31 to June 4 in Chicago, on the shores of Lake Michigan. Professor Jill Hamilton Reeves from the University of Kansas Medical Center shared the results of the SWOG S1600 study at the conference, exploring the impact of immunonutrition on the…
-
Immune Checkpoint Expression Patterns on T Cell Subsets in Light-Chain Amyloidosis: VISTA, PD-1, and TIGIT as Potential Therapeutic Targets
In the dynamic field of hematology and oncology, innovative treatments for systemic amyloid light chain (AL) amyloidosis are essential. Recent research, led by Professor Yangqiu Li from the Institute of Hematology, School of Medicine, Jinan University,, explores immune checkpoint expression patterns in AL amyloidosis. This study investigates VISTA+, PD-1+, Tim-3+, and TIGIT+ T cells in…
-
EHA Expert Interview | Professor Lihua Qiu from Professor Huilai Zhang’s Team Unveils PGI-FL, MCL Research Advances, and New Mechanisms of CD58
The 29th Annual Meeting of the European Hematology Association (EHA) was held from June 13-16, 2024, in Madrid, Spain. As the largest international conference in the field of hematology in Europe, it attracts numerous renowned experts and scholars each year to share and discuss innovative concepts, the latest scientific research, and clinical study results in…
-
EHA China Voice | Professor Li Wang’s Team: Two Studies on DLBCL MRD Monitoring and Orelabrutinib in iNHL Treatment Featured at EHA
The 29th Annual Meeting of the European Hematology Association (EHA) was grandly held in Madrid, Spain, from June 13 to 16, 2024. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from all over the world each year to share and discuss innovative ideas and the latest…
-
Expert Viewpoint: Professor Jun Li on Comprehensive Management of HBV Reactivation Related to Antitumor Treatment
In a study conducted by Metzler F et al. from 2005-2007, involving 258 patients who received one course of Rituximab treatment, 46% had received the hepatitis B vaccine, 11% were Anti-HBc/anti-HBs positive, and less than 1% were HBV DNA positive. The study found that the average Anti-HBs level in vaccinated individuals dropped significantly from 80…
-
ISTH Academician’s Voice | Academician Heyu Ni: Global Chinese Scientists Leading New Directions in Thrombosis Research
From June 22 to June 26, 2024, the 32nd International Society on Thrombosis and Haemostasis (ISTH 2024) Congress was held in Bangkok, Thailand. As the most influential international event in the field of thrombosis and hemostasis, the ISTH Congress attracts thousands of top experts and scholars from around the world with its profound academic impact…
-
Asciminib (ASC) as First-Line Treatment for Newly Diagnosed CML Shows Superior Efficacy, Safety, and Tolerability Compared to Current TKIs
Chronic myeloid leukemia (CML) requires long-term treatment, emphasizing the importance of both efficacy and long-term safety and tolerability to achieve treatment goals, including treatment-free remission (TFR). Asciminib (ASC) is the first specific inhibitor targeting the ABL myristoyl pocket (STAMP) of BCR:ABL1, offering high specificity and minimal off-target effects. From June 13-16, 2024, the 29th Annual…
-
Zanubrutinib Combined with R-Chemo Shows Significant Efficacy and Good Safety as First-Line Treatment for Newly Diagnosed Mantle Cell Lymphoma
Lymphoma, a common malignant tumor of the hematological system, has always been a focus of research for innovative and optimized treatment strategies. In recent years, with the rise of immunotherapy and targeted therapy, lymphoma treatment strategies are undergoing revolutionary changes. The 29th Annual Meeting of the European Hematology Association (EHA) was grandly held from June…
Connecting Medical Expertise through Media